Previous close | 14.00 |
Open | 13.95 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 13.95 - 14.00 |
52-week range | 8.56 - 14.28 |
Volume | |
Avg. volume | 670 |
Market cap | 175.017M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.21 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 21.30 |
BORDEAUX, France, May 25, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.
BORDEAUX, France, May 02, 2023--Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on Wednesday, May 24, 2023, at 2 p.m., at 1 rue Lafaurie de Mondabon, 33000 Bordeaux.
BORDEAUX, France, April 27, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces the publication of its 2022 Universal Registration Document (URD) approved by the French Financial Markets Authority (Autorité des Marchés Financiers (AMF)) on April 26, 2023, under number R.23-018.
BORDEAUX, France, April 24, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces the publication of an initiation report by Degroof Petercam, an independent Belgian-rooted investment bank.
BORDEAUX, France, April 03, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announced its annual results for the year to December 31, 2022.
BORDEAUX, France, March 21, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, eligible for PEA-PME equity savings plans) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its participation in two symposiums marking World Down Syndrome Day.
BORDEAUX, France, January 31, 2023--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its indicative financial calendar for the financial year 2023.
BORDEAUX, France, December 16, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, announces today the recruitment of the first patient for its phase 1/2 trial of AEF0217 in participants with Down syndrome.
BORDEAUX, France, November 15, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, announces today positive results from its phase 1 clinical trials in healthy volunteers with its drug candidate AEF0217. AEF0217 is being developed for the treatment of cognitive deficits caused by a hyperactivity of the CB1 receptor, and as a first indi
BORDEAUX, France, October 04, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces today that Pier Vincenzo Piazza, CEO of Aelis Farma, has received the Entrepreneur of the Year 2022 award from auditing and consulting firm Ernst and Young, in the "Scale-Up" category.
BORDEAUX, France, September 27, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces that its half-year financial report has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers).
BORDEAUX, France, September 26, 2022--Regulatory News: Aelis Farma (Paris: AELIS)(ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its half-year results for the period ended June 30, 2022 and takes stock of its development.
BORDEAUX, France, September 22, 2022--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its participation as a speaker at the Addiction 2022 international conference to be held from September 25 to 28, 2022 in Sardinia, Italy.
BORDEAUX, France, June 07, 2022--Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 – ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the « Company »), informs its shareholders and the financial community that the Company’s Ordinary General Meeting will be held on Tuesday, June 28, 2022 at 2 p.m., at Centre Broca Nouvelle Aquitaine, 11 rue Albert Marquet, 33000 Bordeaux.